Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. (MGTA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mgta · stock forecast · 10 analysts (3M) · FMP · updated Apr 30, 2024
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.70
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.69 | ↓ 1.20% |
1-day model range: $0.68–$0.7. Peak: $0.7 (-1.20%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MGTA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-02-28 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-01-26 | Cowen & Co. | Downgrade ↓ | Outperform→Market Perform |
| 2023-01-26 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-01-26 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2023-01-25 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-01-25 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2023-01-25 | Cowen & Co. | Downgrade ↓ | Outperform→Market Perform |
| 2022-12-21 | BTIG | Maintains | Buy→Buy |
| 2022-12-20 | BTIG | Maintains | Buy→Buy |
| 2022-08-25 | Goldman Sachs | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Magenta Therapeutics, Inc. (MGTA) stock. Of the recent 37 rating actions, 4 were upgrades and 12 were downgrades. 10 analysts currently cover MGTA.
Analyst Recommendation Trends
MGTA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast MGTA EPS of $— for the current fiscal year, based on estimates from 0 analysts. The MGTA revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MGTA stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MGTA price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The MGTA short-term stock prediction for tomorrow is $0.69 (-1.20%).
Magenta Therapeutics, Inc. trades on NASDAQ under the ticker MGTA. The MGTA stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
MGTA forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month MGTA price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.70.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.